Perth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) and the CSIRO have entered into a research collaboration agreement.

The Australian Stock Exchange has created a market that attracts not only local biotechnology companies, but also gives opportunities to foreign companies that would be unable to attract capital in their own markets. Helen Schuller reports.

UK-based NeuroSolutions, the fully owned subsidiary of neurology-focused biotech NeuroDiscovery (ASX:NDL), is to receive about AUD$100,000 for providing electrophysiology services to drug development company Senexis over the next four months.

NeuroSolutions, the UK based subsidiary of newly listed neurology-focused biotech company NeuroDiscovery (ASX:NDL) has identified and selected Sigma Aldrich to provide scale-up and manufacturing services in relation to its lead pain drug candidate, NSL-043, which is due to enter a phase I clinical trial later this year.

NeuroSolutions, a subsidiary of newly listed neurology-focused biotech company NeuroDiscovery (ASX:NDL) has entered into a collaborative agreement with Epichem, a subsidiary of PharmAust (ASX:PAA) to assist with the development of one of NeuroSolutions' lead pain drug candidates, NSL-036.

Perth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) listed today on the Australian Stock Exchange at AUD$0.21, one cent above its issue price of $0.20.

NeuroDiscovery, a Perth-based neurology-focused biotech company, has lodged an IPO prospectus with ASIC to raise funds and acquire 100 per cent of NeuroSolutions, a UK-based service provider and drug discovery company.

Xceed Biotechnology has listed on the ASX (ASX: XBL) at a premium to its placement price of AUD$0.20. At the time of writing the telco turned biotech company, was trading at $0.26, down almost 20 per cent from its opening price of $0.30.